ATHE on Nasdaq
ALTERITY THERAPEUTICS LTD
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with KAZIA THERAPEUTICS LTD or Immutep, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in AUD, the currency the company reports in.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Interest income | 1.7M AUD | 446.3K AUD | 268.4K AUD |
| Other income | 3.6M AUD | 7.6M AUD | 4.0M AUD |
| Intellectual property expenses | -262.8K AUD | -127.5K AUD | -214.3K AUD |
| General and administration expenses | -10.5M AUD | -5.5M AUD | -4.8M AUD |
| Research and development expenses | -17.6M AUD | -14.4M AUD | -18.6M AUD |
| Other operating expenses | -283.9K AUD | -87.3K AUD | -5.2K AUD |
| Other gains / (losses) | 90.1K AUD | -67.1K AUD | 261.2K AUD |
| Loss before income tax expense | -23.3M AUD | -12.1M AUD | -19.1M AUD |
| Income tax expense | -113.5K AUD | -68.1K AUD | -46.1K AUD |
| Loss for the year | -23.4M AUD | -12.1M AUD | -19.1M AUD |
| Other comprehensive loss | -40.8K AUD | 0 AUD | 0 AUD |
| Total comprehensive loss for the year | -23.4M AUD | -12.1M AUD | -19.1M AUD |
| Loss per share (basic and diluted - cents per share) (adjusted) (in AUD per share) | -11.12 AUD | -9.50 AUD | -26.20 AUD |
| Weighted average number of ordinary shares used in computing basic and diluted net loss per share (in shares) | 210.5M shares | 127.9M shares | 73.0M shares |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | 37.3M AUD | 33.2M AUD | 12.6M AUD |
| Trade and other receivables | 7.7M AUD | 3.9M AUD | |
| Other current assets | 811.8K AUD | 8.8M AUD | |
| Total Current Assets | 45.8M AUD | 45.9M AUD | |
| Property and equipment | 302 AUD | 3.8K AUD | |
| Right-of-use assets | 190.3K AUD | 151.3K AUD | 154.7K AUD |
| Total Non-Current Assets | 190.6K AUD | 155.2K AUD | |
| Total Assets | 46.0M AUD | 46.0M AUD | |
| Trade and other payables | 2.0M AUD | 2.6M AUD | |
| Provisions | 1.0M AUD | 875.9K AUD | |
| Other current liabilities | 133 AUD | 139 AUD | |
| Lease liabilities | 55.2K AUD | 66.9K AUD | 107.1K AUD |
| Current tax liabilities | 48.4K AUD | 16.3K AUD | |
| Total Current Liabilities | 3.2M AUD | 3.5M AUD | |
| Lease liabilities | 138.3K AUD | 88.5K AUD | 51.9K AUD |
| Total Non-Current Liabilities | 138.3K AUD | 88.5K AUD | |
| Total Liabilities | 3.3M AUD | 3.6M AUD | |
| Net Assets | 42.7M AUD | 42.4M AUD | |
| Issued capital | 282.5M AUD | 262.9M AUD | 223.2M AUD |
| Reserves | 5.8M AUD | 5.3M AUD | 4.8M AUD |
| Accumulated deficit during the development stage | -245.6M AUD | -225.9M AUD | -214.2M AUD |
| Total Equity | 42.7M AUD | 42.4M AUD | 13.8M AUD |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Payments to suppliers and employees | -24.1M AUD | -17.5M AUD | -21.4M AUD |
| Interest received | 1.6M AUD | 446.3K AUD | 269.1K AUD |
| R&D tax refund | 0 AUD | 5.6M AUD | 8.6M AUD |
| Interest paid | 0 AUD | 0 AUD | -7.2K AUD |
| Income tax paid | -81.3K AUD | -68.1K AUD | -58.0K AUD |
| Net cash flows used in operating activities | -22.5M AUD | -11.5M AUD | -12.6M AUD |
| Payments for purchase of plant and equipment | 0 AUD | 0 AUD | -5.7K AUD |
| Receipt from / (payments for) term deposit | 7.5M AUD | -7.5M AUD | 0 AUD |
| Net cash flows generated from / (used in) investing activities | $7.5M | -$7.5M | -$5.7K |
| Proceeds from issue of ordinary shares | $20.4M | $42.6M | $10.1M |
| Payment of share issue costs | -1.1M AUD | -2.8M AUD | -918.0K AUD |
| Principal elements of lease payments | -136.6K AUD | -127.1K AUD | -10.4K AUD |
| Net cash flows generated from financing activities | 19.1M AUD | 39.7M AUD | 9.2M AUD |
| Net increase / (decrease) in cash and cash equivalents | 4.1M AUD | 20.7M AUD | -3.4M AUD |
| Exchange rate adjustments on cash and cash equivalents held in foreign currencies | 51.6K AUD | -198.4K AUD | 260.4K AUD |
Former names
- PRANA BIOTECHNOLOGY LTDMay 29, 2002 to Apr 8, 20192
Recent filings
- Oct 9, 20266-K
- Oct 5, 20266-K
- Sep 25, 20266-K
- Sep 23, 20266-K
- Sep 18, 20266-K
- Sep 18, 2026S-8
- Sep 16, 20266-K
- Sep 8, 20266-K
- Sep 8, 20266-K
- Sep 8, 20264 PRIMARY DOCUMENT
- Sep 8, 20264 PRIMARY DOCUMENT
- Sep 3, 20266-K
- Sep 2, 20266-K
- Sep 2, 20266-K
- Sep 1, 20266-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9